Dr. David R. Wise, M.D., PH.D.
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Perelman School of Med at the University of Pennsylvania (2011)
- Years since graduation
- 15
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 335
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Medical school: Perelman School of Med at the University of Pennsylvania
- 2011Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
NY license 270704 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- NYU Langone Hospitals New York, NY
Medical groups
- New York University (6,134 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 335
- Services billed
- 938
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 387 | 216 |
| Established patient office or other outpatient visit, 20-29 minutes | 162 | 124 |
| Established patient office or other outpatient visit, 40-54 minutes | 127 | 70 |
| New patient office or other outpatient visit, 60-74 minutes | 76 | 76 |
| Telephone medical discussion with physician, 11-20 minutes | 54 | 41 |
| Telephone medical discussion with physician, 21-30 minutes | 29 | 21 |
| Telephone medical discussion with physician, 5-10 minutes | 16 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in New York, NY | 210 |
| Abiraterone Acetate | 197 |
| Nubeqa (darolutamide) | 151 |
| Orgovyx (relugolix) | 145 |
| Xtandi (enzalutamide) | 117 |
| Bicalutamide | 57 |
| Lynparza (olaparib) | 43 |
| Dexamethasone Other prescribers in New York, NY | 38 |
| Tamsulosin Hcl Other prescribers in New York, NY | 27 |
| Oxycodone Hcl Other prescribers in New York, NY | 25 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 7 payments worth $4,216 in total to this clinician.
| Pfizer Inc. | $2,360 |
|---|---|
| Janssen Biotech, Inc. | $1,388 |
| Bayer HealthCare Pharmaceuticals Inc. | $291 |
| Blue Earth Diagnostics | $178 |
| Consulting Fee | $3,488 |
|---|---|
| Food and Beverage | $729 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Mar 12, 2025 | Consulting Fee TALZENNA · ONCOLOGY | $2,100 |
| Janssen Biotech, Inc. Sep 19, 2025 | Consulting Fee ERLEADA · Oncology | $1,388 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 11 industry-funded studies in 2025, from 6 companies. The companies reported $1,014,478 in research payments for these studies, mostly to the institutions running them.
- A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-63723283 (cetrelimab) for Metastatic Castration-Resistant Prostate Cancer
Janssen Research & Development, LLC - A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT03972657 - A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2 Versus Placebo for Metastatic Castration-resistant Prostate Cancer
Janssen Research & Development, LLC - A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 and Pembrolizumab in Combination with Other Investigational Agents in Subjects with High-risk Non-muscle-Invasive Bladder Cancer NMIB…
Merck Sharp & Dohme LLC - A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy versus Perioperative Placebo Neoadjuvant Chemotherapy in Cisplatin-Eligible Participants with Muscle…
Merck Sharp & Dohme LLC - A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
Eli Lilly and Company · Active, not recruiting · NCT05288166 - M19-345 - Study to Determine the Safety Tolerability Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metasta…
AbbVie Inc. - A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer mHSPC KEYNOTE-991
Merck Sharp & Dohme LLC - Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors
AbbVie Inc. · Active, not recruiting · NCT03821935 - A Phase II, Randomized, Open-label, Multi-center Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.